Latest News

To estimate the negative predictive value (NPV) of prostate mpMRI in the detection of clinically significant (Gleason ≥7) prostate cancer (csPCa) at long-term follow-up (median 6.7 years, range 2. 6-10.7 years), in men with negative pre-MRI biopsy and to assess the diagnostic performance of mpMRI in detecting csPCa over this time. Following Institutional REB-approval, men […]

Stereotactic radiotherapy is an emerging treatment option for patients with inoperable renal cell carcinoma (RCC). Haemorrhage has not previously been reported to occur as a result of Stereotactic Body Radiotherapy (SBRT) to the kidney for primary RCC. We report an acute haemorrhage in a patient who received only one of three planned fractions of SBRT […]

Adjuvant radiation therapy has been recommended for patients at higher risk of relapse from renal cell carcinoma (RCC) to improve disease-free survival (DFS) and overall survival (OS) after radical nephrectomy. To quantify the benefit of adjuvant radiation therapy. A systematic review of electronic databases identified publications exploring the association between adjuvant radiation therapy and locoregional […]

Temsirolimus has level 1 evidence for initial treatment of poor-risk patients with advanced renal cell carcinoma (mRCC), but its efficacy has not been directly compared with an antiangiogenic tyrosine kinase inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKi]) in this setting. To evaluate temsirolimus versus pazopanib as first-line therapy in patients with […]

Background: Tropomyosin-1 (TPM1) has long been known to be an actin-binding cytoskeletal protein. Multiple recent studies have revealed that TPM1 is down-regulated in various malignant tumors, including renal cell carcinoma (RCC). Methods: To further verify its role in RCC, transfection of a reconstructed plasmid was used to bi-directionally regulate TPM1 levels. A colony formation assay, […]

I continue to be surprised by the biology of prostate cancer, and how much guessing we are still doing. The good news is the number of tools in the tool chest is increasing. Also, even in situations where they don’t direct our actions, our ability to gain an understanding of the molecular underpinnings of the […]

Charles Ryan: Hello from ASCO 2019. I’m delighted today to be joined by Dr. Jonathan Rosenberg, who is Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. Thank you for joining us, Jonathan. Today we’re going to talk about your Phase III trial in bladder cancer, CALGB 90601. This is a study that […]

Phase I Study of Hyperthermia Combined With High Dose Rate Salvage Radiotherapy for the Treatment of Radiation Recurrent Prostate Cancer Condition: Recurrent Prostate Carcinoma Intervention: Radiation: High-Dose Rate Brachytherapy Procedure: Hyperthermia Treatment Purpose: This phase I trial studies the side effects and best way to give hyperthermia and high dose rate radiation therapy in treating […]

A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis Condition: Germ Cell Tumour Intervention: Drug: Combination Chemotherapy Purpose: The treatment of germ cell tumours is considered to be one of the major successes in the area of cytotoxic chemotherapy. Even in patients who relapse after first line therapy, a […]